BERTIS, a proteomics technology company that uses bioinformatics and proteomics to find key biomarkers for detecting cancers and various diseases.
Bertis stands out in the field of quantitative proteomics with its comprehensive technology platform. They encompass the entire process, from identifying protein biomarkers to developing diagnostic solutions. This allows them to conduct in-depth research and development on diagnostic solutions for various cancers and major diseases.
Global First: MASTOCHECK, the Proteomics-Powered Breast Cancer Blood Test
MASTOCHECK is an innovative and convenient test method that detects early breast cancer with an accuracy of 92% (based on the patent) by using only a very small amount of blood. BERTIS has developed multiple markers that can detect early breast cancer with an accuracy of 92% through the identification of multiple proteins that are expressed sensitively in early-stage breast cancer and combinations of certain proteins that demonstrated high accuracy and reproducibility among these combinations.
Development Process
MASTOCHECK was developed by a team led by Professor Dong-Young Noh, a world-renowned authority on breast cancer at Seoul National University. After analyzing approximately 600,000 proteins and selecting 3 markers exhibiting optimal accuracy, the highest accuracy was obtained by adding Bertis’ own algorithm that enhances accuracy.
After several years of repeated validation work, a medical device product license was obtained from the MFDS in January 2019. To date (as of September 2023), MASTOCHECK has been introduced to about 400 hospitals and screening institutions nationwide, with priority given to large screening institutions.
Key Points of MASTOCHECK:
- Innovative and convenient: MASTOCHECK appears to be a new and easier way to detect early breast cancer compared to traditional methods.
- High accuracy: Based on the patent, the test claims a 92% accuracy rate, which is impressive if confirmed in further research.
- Blood-based: Unlike mammograms that require radiation and physical discomfort, MASTOCHECK requires only a small amount of blood, making it a potentially less invasive option.
- Multiple protein markers: The test relies on identifying several proteins that are specifically expressed in early-stage breast cancer.
- Combination approach: BERTIS has identified specific protein combinations that provide high accuracy and reproducibility.
Click here to contact Bertis
View more: World’s First Proteomics-Based Blood Test Solution for the Early Diagnosis of Breast Cancer
